Concord Biotech Files FY26 Business Responsibility and Sustainability Report

Concord Biotech Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as mandated by SEBI regulations. The report, which is part of the company's 41st Annual Report, details its operations, products, and employee data. The company's business activities primarily involve the manufacturing of pharmaceuticals, with 78.6% of turnover from Active Pharmaceutical Ingredients (APIs) and 21.4% from finished formulations. Concord serves over 300 customers in more than 70 countries, with exports contributing 46.56% to its total turnover. The report also includes details on its standalone reporting basis, reasonable assurance from its assurance provider, and contact information for queries.